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Abstract: Recently, there has been an 
increased focus on improving the quality of 
drug supply data at EU level, underpinned by 
a number of policy developments, notably the 
Council of the European Union’s conclusions 
of 15 November 2013 regarding supply and 
supply reduction within the implementation 
of the EU Drug Action Plan (2013–16). 
Mindful of the uncertainties and challenges 
of measuring an increasingly dynamic illicit 
drug market, while building on the positive 
work in the EU Member States, the European 
Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) has been a driving force 
for improving supply metrics and indicators.
This paper presents a snapshot of the 
evolution of the EMCDDA’s conceptual 
framework for supply monitoring. It describes 
a dynamic system based upon three linked 
thematic areas: drug markets, drivers and 
facilitators; drug-related crime, harms and 
other consequences; and reduction of and 
responses to drug supply. Each area is 
served by a set of (overlapping) indicators. 
The framework was developed to logically 
organise the multifaceted aspects of illicit 
drug markets and supply, going beyond 
the EMCDDA’s current core monitoring by 
integrating new data sources and novel 
measurement methodologies.
The present work contributes to the concerted 
effort in the EU to establish a coherent drug 
supply monitoring framework, including 
identifying new sources of information. While 
work to further enhance the existing supply 
indicators should remain a priority, baselines 
should also be established in new priority 
areas to allow enhanced monitoring of the 
supply side of the drugs phenomenon, thus 
providing a balanced set of drug policy tools. 
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I Background and aims
The EMCDDA, the European Commission and Europol have 
been working on the development of indicators of drug supply 
and drug supply reduction for a number of years. The work 
was been informed by two European conferences, the first 
in Brussels in 2010 and the second in Lisbon in 2012. As 
a result of these conferences, a framework was developed 
for collecting data to support the aims of providing a sound 
understanding of the situation, identifying new threats, 
targeting activities and considering the impact of policy 
measures. The foregoing work proposed three key indicators — 
drug markets, drug supply reduction and drug-related crime — 
supported by a data collection and contextual component that 
contributes to one or more of the key indicators. The impetus 
for the development of these was provided by the Council 
conclusions of 15 November 2013 (Council of the European 
Union, 2013), which called upon Member States, the EMCDDA 
and Europol to improve the monitoring of the drug supply in 
the EU. Many of the aspirations raised and improvements 
called for in those conferences and documents have since 
been adopted. 
The Council conclusions of 2013 (Council of the European 
Union, 2013) defined the priorities for the EMCDDA’s efforts. 
By the end of 2016, significant progress had been made, 
including revision and adoption by the Member States 
of indicators on drug seizures, drug law offences, prices, 
purity and production facilities, as well as the methodology 
for estimating market size. The EU Policy Cycle on serious 
and organised international crime has radically changed 
the way that the EMCDDA interacts with Europol and the 
Member States, giving it access to highly relevant contextual 
information by interacting with key players in the field, most 
notably law enforcement officers. As a result, the data collected 
are more amenable to credible analysis. The EU Drug Markets 
Reports of 2013 and 2016 have been key to understanding our 
strengths and highlighting important gaps in our knowledge 
and areas for further development in this field. This paper 
sets out to document the recent evolution of the conceptual 
framework for supply monitoring and identifies and describes 
further improvements in existing EMCDDA supply data, 
additional data sources, novel measurement methodologies 
and new analyses. 
I Method 
The process for developing the supply framework involved (1) 
a review of the relevant published literature, (2) an internal 
consultation, and (3) expert engagement: 
1. A review was undertaken from November 2015 to April 
2016 (reported elsewhere) of policy documents and 
published international research in relation to drug markets 
and drug-related crime. 
2. An internal consultation process, informed by the literature 
review, took place between July 2016 and February 2017, 
resulting in an expanded framework. 
3. A critical review was carried out of the overall framework 
and individual thematic areas by a network of stakeholders 
supporting supply indicators that was drawn from the drug 
research, policy and law enforcement communities; the 
EMCDDA hosted an expert meeting on the topic in Lisbon, 
2–3 March 2017. 
I Conceptual framework for monitoring drug supply 
The framework comprises three linked thematic areas. These 
were initially conceptualised as covering drug markets, 
drug-related crime and drug supply reduction. In the light of 
developments in drug markets and supply activities and their 
wider impacts and in tackling the drivers and enablers of 
drug supply, the conceptual framework has been developed 
further and the three thematic areas broadened (Figure 1).
Each area is served by sets of (overlapping) indicators, 
informing each other. The first part of this section outlines 
six general criteria that supply indicators need to satisfy; it 
then takes each area in turn – focusing on key issues around 
data, methods and analysis. The proposed developments are 
outlined in Figure 2, structured by thematic area, although 
it is recognised that there are multiple overlaps and no 
indication of hierarchical significance.
I General criteria 
The following criteria have been identified as necessary 
features of supply monitoring (adapted from OECD, 2008):
1. the ability of the overarching conceptual framework for 
supply to address knowledge gaps and thereby inform 
evidence-based policy and practice; 
2. the accuracy of the data and credibility of the sources; 
3. the timeliness of making data and information available (to 
ensure relevance); 
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4. accessibility in terms of overcoming restrictions (and/or 
cost); 
5. ease of interpretation in terms of documentation and 
metadata; and 
6. coherence in terms of definition and format across 
jurisdictions and time.
I Drug markets, drivers and facilitators
Current situation
The starting point for developing a supply side data 
infrastructure is an understanding of how drug markets 
operate. Supply refers to the production and distribution 
capacity of the market for drugs such as heroin, cocaine 
and cannabis. Producers, traffickers and sellers are seen as 
responding to price and risk. Increases in the risks of arrest, 
drug seizure or asset confiscation will result in a downwards 
shift in the supply curve, i.e. at any given price a smaller 
quantity of drugs will be offered. The price itself will be 
determined by the interaction of the supply curve and the 
demand curve, as captured in the standard economic market 
diagram, showing the result of a shift in the supply curve 
(Figure 3). The supply curve can shift for reasons other than 
policy interventions; for example, a drought in Afghanistan 
may raise the farm-gate price of opium and hence the retail 
price of heroin. Technological changes, such as improved 
methods of growing cannabis, can also lead to a supply-
induced decline in prices.
A major challenge then is to separate the effects of supply 
side shifts from those that are the result of changes in 
demand, for which a rich set of indicators is already available. 
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FIGURE 1
The EMCDDA drug supply monitoring system
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For example, price may rise because of a shift upwards in the 
supply curve or as a result of a shift in consumer tastes that 
shifts the demand side upwards. 
This thematic area encompasses the whole supply chain, 
from illicit production/cultivation to trafficking and sale. As 
part of the most recent developmental work, the focus is 
broadened to: 
 ■ traditional measures of enforcement (drug seizures and 
arrests for drug law offences other than possession) 
alongside measures to dismantle production/cultivation 
facilities (synthetic drugs, cocaine secondary extraction 
and cannabis); these provide numerators for measures of 
the risks faced by producers and traffickers;
 ■ estimates of retail market size (from population surveys); 
these provide the denominator for calculation of those 
risks;
 ■ perceived availability, which supplements price as a 
measure of market tightness; this is also generated by 
population surveys; 
 ■ price and purity data at three market levels (retail, middle 
level and wholesale); supply side measures are specific to 
different market levels; for policymakers it is important to 
be able to assess separately the impacts of interdiction, 
enforcement against trafficking and enforcement 
against low-level dealers; while prices are fundamental 
to assessing supply-side reduction measures, they can 
be interpreted only along with the other supply side and 
demand side indicators. 
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FIGURE 2
Thematic areas, domains and potential indicators for developing the EMCDDA 
drug supply monitoring system
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A brief description of the core measures is provided below, 
along with reference to details of current data collection 
methods: 
 ■ Drug seizures: annual collection in a standardised table 
from each Member State, including numbers and quantities 
at the three market levels for all drugs. Member States may 
opt to report on precursor and on country of production, 
transit and destination (EMCDDA standard table 13 and 
protocol for reporting drug seizures, 2016).
 ■ Drug purity and tablet content: annual collection in a 
standardised table from each Member State, including 
purity, potency and tablet content for all drugs and at 
the three market levels (for powdered drugs) (EMCDDA 
standard tables 14 and 15 and protocol for reporting purity 
data, 2016).
 ■ Drug prices: annual collection in a standardised table from 
each Member State, including average drug prices at the 
three market levels for all drugs (EMCDDA standard table 
16 and protocol for reporting price data, 2016).
 ■ Drug law offences: annual collection in a standardised table 
from each Member State, including number of offences 
by Institute for Conflict, Cooperation and Security–United 
Nations Office on Drugs and Crime category and drug type 
Price
Quantity
D
S
2
S
1
P
2
P
1
Q
1
Q
2
FIGURE 3
The effect of a shift in the drug supply curve for developing 
the EMCDDA drug supply monitoring system
A demand (D) curve maps the relationship between price (P) and the quantity (Q) 
consumers are willing to purchase. The supply (S) curve maps the relationship 
between price and the quantity that producers (distributors) are willing to provide.
After Caulkins and Reuter, 2010.
(EMCDDA standard table 11 and protocol for reporting 
drug law offences, 2016).
 ■ Perceived availability: annual collection through the 
European Web Survey on Drugs.
Challenges 
Both seizures and drug law offences statistics have been 
criticised for being inaccurate measures of drug markets, 
as they are influenced by both law enforcement tactics and 
priorities and the scale of the market and drug-related crime. 
Nevertheless, it is recognised that these data are available 
at near zero cost as by-products of administrative record 
systems across Member States. Therefore, the challenge is 
their correct interpretation. 
Furthermore, while the above indicators can be an important 
aid to understanding the nature of the drug market, and can 
help to provide a map of the sources, range and quality of 
available drugs, they convey no information about the range 
of actors, technologies and other factors that contribute to 
making drugs available to users. 
Finally, an overall challenge to plans for core data collection 
relates to the limited timeliness. Relying solely on annual 
figures flattens changes that might have occurred in the 
meantime and hampers timely response (e.g. in terms of 
a shift in the focus of data collection, research priorities or 
wider alerts).
Areas for improvement 
Interpretational challenges can be addressed by using 
contextual information. Qualitative information should also be 
embedded in the quantitative framework to inform areas such 
as law enforcement priorities, funding cycles and allocation. 
This will give an indication of the extent to which these data 
can be considered an accurate representation of the markets. 
This contextual approach will provide confidence for cross-
country comparisons of seizures and drug law offences.
In addition, qualitative contextual information regarding 
seizures (e.g. method of concealment, trafficking modus 
operandi) need to be emphasised in the data collection 
framework. More effective enforcement should lead to the 
use of more expensive models of trafficking.
Utilising information from demand indicators can help 
answer questions on the supply side in relation to the market 
composition (i.e. products and availability), changes occurring 
in this composition, the ratio of demand–supply). Demand 
side information should be used in conjunction with supply 
indicators to give a fuller picture of drug markets and to 
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allow methodological tools to be developed. For example, an 
increase in seizures at the same time as a decline in demand 
side indicators for the drug and an increase in price suggests 
that law enforcement is indeed seizing a higher percentage of 
the total drug supply.
Supplementing routine data collections with ad hoc research 
or access to external parallel data collections will improve 
timeliness. Opportunities need to be identified and exploited 
for timely access to data and information to describe, 
for instance, market changes and emerging trends — an 
early warning system that is not necessarily systematic 
but can give a first indication of change — to allow further 
investigation and follow up. It is conceivable that such an 
approach can be taken to monitor changes in the type of 
drug trafficker, emerging drug dealing locations, selling/
trafficking methods, production processes and precursors. 
Possible sources here include intelligence information and 
networks of experts; surveys may also need to be developed 
to address these information needs. The new internet surveys 
of experienced users are potentially a rich and very cheap 
method for developing data on emerging methods of retailing.
A further benefit of parallel data collections is the flexibility 
they offer, potentially highlighting fluctuations that might 
have been missed in routine annual figures. In relation to the 
price and purity indicators, core monitoring can integrate 
high-frequency data collection in select localities (regions/
cities with strategic importance for trafficking/importation) 
to allow identification of the detail in the broader price, purity 
and purity-adjusted price patterns.
Finally, in areas where quantification is not feasible at 
present, access to information that might not be considered 
statistically rigorous should be explored, including 
constructing and using rating scales among a broad 
network of respondents — for example, assessment by law 
enforcement of the level of drug-related crime, akin to the 
work undertaken in the Czech Republic (1).
To facilitate and improve cross-indicator analyses, continued 
work needs to explore and validate (or otherwise) existing 
choices around grouping seizures by size across different 
drug types. The use of prices to study the markets can be 
improved by categorising and access to data in relation 
to drug source (production/cultivation), importation and 
domestic retail levels. This offers greater precision than the 
current ambiguity arising from attempting to attribute prices 
to fluctuating boundaries around the middle market level.
In relation to the last point, more work is required on 
understanding the intermediate level between retail and 
wholesale markets. Existing work (Caulkins et al., 2016; 
(1) Since 2003, in the Czech Republic, this has been referred to as ‘secondary 
drug crime’.
Tzvetkova et al., 2016), based on qualitative methods, can be 
supplemented by studying the relations between different 
actors using social network analysis. The latter approach can 
be applied to all markets levels to study the range of actors 
involved in the drug markets as well as organised crime 
groups involved in drug production and distribution. The 
monitoring of online drug sales through user forums and the 
darknet can provide further insights in this area.
I Drug-related crime, harms and other consequences
Current situation 
This thematic area represents a complex category, with 
many possible definitions of ‘drug-related crime’. To date, 
it has been informed by drug law offences data available at 
European level — measures of arrests for possession or use 
and supply by drug type. 
The European security agenda explicitly highlights a need to 
understand the interactions that exist between drug-related 
crime and the operation of the drug market, on the one hand, 
and other areas of criminality, the activities of organised 
criminal groups and other sources of security threats, on 
the other. Such overlaps were also highlighted in the 2016 
European Drug Markets Report, which clearly suggested 
that threats in this area were increasing due, in part, to the 
changing business models used by transnational organised 
crime groups. In addition to these major security threats, it 
is also important to support the development of a broader 
understanding of the ramifications of the drug market, as 
these can represent important hidden costs to society. 
Challenges 
Broadening the scope of this area is necessary, so that 
it begins to reflect the wider set of crime types that are 
associated with the operation of illicit drug markets, i.e. 
violent offences, intimidation, loss of amenities, to provide an 
understanding of the harmful effect of drug markets on the 
security of individuals, communities and institutions. Beyond 
security, other dimensions of market-related consequences 
should be considered, including social, economic and 
environmental impacts. 
This is a challenging area and, although some core monitoring 
tools exist, overall this area remains to be developed. There 
will continue to be high demand for quantitative measures 
of drug-related burden and harm. Mapping the sources of 
harms and beginning to quantify them could be improved 
by introducing improved coding or ‘tagging’ procedures in 
statistical recording systems (e.g. corruption cases tagged 
with a drug marker). 
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Areas for improvement 
The current focus should be expanded from the offence 
types recorded in drug law offences data to include other 
drug-related offences, as conceptualised by Goldstein 
(1985): psychopharmacological, for example, driving under 
the influence of drugs; economic–compulsive offences or 
acquisitive offences, such as theft, extortion and street crime 
(Farabee et al., 2001; Hutchinson et al., 2000); and systemic 
offences, such as drug market-related homicide and money 
laundering. 
Establishing a baseline for future comparisons of drug-related 
activity in relation to harms will need to consider prioritising 
which data collections are to have a drug ‘tag’ introduced and 
incrementally improving data availability and quality. While 
data on drug-related predicate offences in relation to other 
crimes (e.g. corruption, money laundering) are not available 
at present, pushing for data to be collected and developing 
the methodologies to access these data would increase 
awareness about the problems and simultaneously attempt 
to provide the tools and metrics to aid police management 
and evidence-based policy formulation.
With regard to drug-related homicide, work is under way 
mapping EU-wide data and sources and exploring the 
feasibility of long-term EU-level monitoring, incorporating 
publicly available data. Building on that, a feasible model for 
data collection, which integrates open source information, 
will be developed .
In the area of anti-money laundering in the EU, macro-
quantification approaches have been documented, which 
is a good starting point (e.g. Project ECOLEF, funded by the 
European Commission Directorate-General for Migration 
and Home Affairs, LS/2009/ISEC/AG/087). Taking a 
case-level approach can be more productive than only 
considering macro-perspectives. One possible approach 
could be to screen and identify relevant (closed) case files 
at Europol’s disposal, producing a comprehensive case 
study compendium — which can then be coupled with a 
macro-level quantification exercise. Further potential data 
sources should be explored, including a Directorate-General 
for Justice and Consumers pilot data collection on money 
laundering in Member States, which includes illicit drug 
trafficking, among other predicate offences. Comparing case 
data with media reports using content analysis could be an 
interesting additional element to exploit.
Access to data should be sought in the area of corruption, 
where drugs would feature as ‘red flags’, particularly in 
public sector categories such as transport, customs, 
maritime. The European Commission receives data from 
most Member States on the treatment of corruption cases in 
the criminal justice system. In addition, the United Nations 
Office on Drugs and Crime is carrying out pilot studies and 
experiments at country level to develop guidelines for sample 
surveys of experience of bribery. Finally, the Organisation for 
Economic Cooperation and Development (OECD) has a pilot 
project looking at bribery cases based on information from 
court judgments. Building on these pilot exercises, a number 
of follow-up measures could be explored to support access to 
drug-related information within these crime areas. 
In addition to direct quantitative measures of drug-related 
crimes, surveys of expert and public perception in a number 
of areas can be developed, focusing on perceived safety 
and security at community level and perceived drug-related 
burden across different types of offence and among a range 
of respondents (e.g. judges, prosecutors, lawyers). 
The frequency of data access, along with other research 
procedures, such as giving incentives to respondents to 
share their experiences, will need to be addressed. An area 
that may be worth exploring is access to airport incident and 
high-risk information in relation to drugs (e.g. deaths of body 
packers). 
A key element in addressing data gaps in the area of drug-
related crime, harms and consequences will be to look 
more broadly for data (i.e. research findings, open source 
information) as well as statistics. Existing measures and 
datasets should be accessed — exploratory analyses may 
then look at how these correlate with our best measures in 
the given area. Examples include, but are not limited to, the 
Corruption Perception Index of Transparency International; 
the European Criminal Records Information System, which 
has recently been piloted for analytical purposes; and the 
Risk Information Form exchange (European Commission).
In the coming years, the potential of wastewater analysis will 
be further explored to establish a baseline for the assessment 
of drug-related environmental impact, in particular in relation 
to events in which raw drug production waste or even finished 
product is dumped in the municipal sewerage system. 
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I Drug supply reduction and responses
Current situation 
At present measures in this area are limited to drug seizures, 
numbers of dealers and traffickers arrested and production/
cultivation facilities dismantled (synthetic drugs, cocaine 
secondary extraction and cannabis). In addition, indicators, 
such as drug affordability, are being developed that utilise 
existing market data for more sophisticated analyses. 
Challenges
Supply reduction and responses are linked to the broader 
concept of reducing the overall scale of the market. 
Accordingly, more effective measures for estimating the 
availability and accessibility of illicit drugs should be 
considered.
A key part in developing this thematic area — including data 
access and analyses — would be to achieve clarity about the 
reason (and there may be multiple reasons) we do it, which is 
also linked to the EMCDDA’s strategy in terms of contributing 
to a healthier and more secure Europe. For the purposes 
of monitoring, the emphasis would be on describing and 
analysing markets and supply; for outcome evaluation, it 
would be on detecting market changes and supply shifts; and 
for planning, it would be on informing policy emphasis and/or 
resource distribution and priority setting.
One of the main challenges would be to separate changes 
occurring as a result of supply influences from those that 
are demand driven. As noted above, progress in this area will 
come from analysing both supply and demand measures 
together. Nevertheless, linking back to the purposes of data 
and information, it will be important to be able to make that 
distinction — for policy and police resource management 
purposes.
On certain topics, particularly around confidential information 
that may hamper law enforcement efforts or prejudice 
ongoing investigations related to priority setting for Member 
States’ police forces (at national or regional levels), it is 
understandable that data may not be readily shared with 
international organisations and alternative sources may need 
to be identified.
Finally, based on current discussions at expert level and the 
EMCDDA’s own past methodological work and experience 
in collecting public expenditure data, there would appear 
to be a common point throughout relating to a range of 
methodological and other problems. Given the limitations, we 
need to consider how these data can be used in a meaningful 
way in the proposed framework.
Areas for improvement 
One approach, based on the prices and risk framework 
(Caulkins and Reuter, 2010; Reuter and Kleiman, 1986), 
would be to access and analyse drug prices at export, import 
and retail levels. With regard, for instance, to heroin and 
cocaine, information can be gathered on: 
 ■ shifts in supply from producer countries — reflected in 
changes in export prices;
 ■ changes in trafficking processes — reflected in the 
difference between export and import prices;
 ■ shifts in domestic supply — reflected in retail prices.
Attention needs to be given to certain conceptual and data 
issues at the analytical stage to account for alternative 
sources of impact (e.g. the appearance on the market of new 
drugs as replacements) and volume discounting on prices, 
particularly at source. Furthermore, different models would 
be needed for different drug types, particularly for synthetic 
drugs, as production takes place in Europe. Finally, there may 
not always be a tangible outcome from law enforcement 
activity, such as arrests, seizures or asset confiscation, 
although criminal operations may be disrupted. 
The wider determinants of supply would need to be 
considered, including, among others, the willingness of 
domestic labour to incur risks from the criminal justice 
system, other market participants and the availability of 
technology and materials for production. 
As well as looking at supply reduction, this thematic area 
should also recognise the contribution of law enforcement 
agencies in reducing harms and the wider consequences of 
markets and supply, and therefore aim to develop measures 
of (perceived) drug-related violence, nuisance and corruption.
The feasibility of developing a framework for law enforcement 
activity prioritisation or evaluation could be explored — a 
framework featuring modules focusing on concepts, data 
and quality. This has the potential to increase interest and 
capacity at Member State level to generate evidence and 
good practice. In addition, providing and recommending 
standardised tools (and guidance or assistance with 
implementation) indicating key areas for assessment may 
introduce a certain level of objectivity and comparability 
across units (e.g. Member State, city) that choose to apply 
it, either to aid resource planning and prioritisation or for 
evaluating effectiveness.
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I Discussion and conclusions
Following a detailed focus on each thematic area within the 
new framework, this final section summarises key overarching 
points and offers an outlook. 
The present work contributes to the incremental, concerted 
effort in an EU context to establish a coherent supply 
monitoring framework, including identifying new sources of 
information.
Building on discussions with supply indicators experts, new 
data sources are being explored and tested. Examples include 
monitoring open source information, drug sales on darknet 
markets, and excreted drugs and metabolites in wastewater. In 
addition, ad hoc research, access to expert groups and existing 
European (including those  outside the EU) data collections 
will need to be explored. 
There will continue to be a high demand for quantitative 
measures in these different areas. Enhancing those measures 
should include organising the contextual information around 
them in a systematic way.
The proposed concept framework is key and will have 
embedded in it further (cross-indicator) analyses, akin to the 
comparison of drug prevalence and market data reported 
recently (Groshkova et al., 2017). In future it will be increasingly 
important to demonstrate the uses to which data is being put 
— to generate further interest in data and quality in this area.
Finally, an openness to new measurement methodologies and 
sources is reflected in shifting the focus away from routine 
data collection from all Member States all the time to include 
staggered data collections and/or selective or targeted 
collection plans. 
The group of experts engaged in the work around the drug 
supply indicators will have a key role in future serving as a 
forum for further data quality improvement as well as a way 
of accessing research findings, intelligence and contextual 
information to inform analysis. Feedback mechanisms for the 
analysis and findings will be sought through other EMCDDA 
networks including Reitox and the reference group.
Future efforts will need to focus on further improving and 
formalising the quality or ‘fitness for use’ of the framework to 
suitably reflect the OECD criteria identified in this paper.
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